Project Grant R01DC023301
- The National Institute on Deafness and Other Communication Disorders awarded New York University School of Medicine $685,327 on July 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate cortical mechanisms of speech planning in Parkinson's disease and non-PD participants. The research brings together neurosurgeons and systems neuroscientists to examine neural dynamics relevant for speech planning using electrocorticography and...
- The National Institute on Deafness and Other Communication Disorders awarded Utah State University $430,379 on May 15, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate entrainment-based interventions for improving communication in people with Parkinson's disease. The research explores whether patients with hypokinetic dysarthria—characterized by mumbled and rapid speech—naturally entrain to, or align with, communication partners...
- The National Institute on Deafness and Other Communication Disorders awarded the University of South Carolina $146,004 on March 16, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to support a transitional research career award (K99/R00) investigating repetitive transcranial magnetic stimulation (rTMS) targeting the anterior temporal lobe for post-stroke aphasia recovery. The award funds a three-arm randomized clinical trial enrolling 60 individuals...
- The National Institute on Deafness and Other Communication Disorders awarded Duke University $547,650 on July 2, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to develop a predictive model of discourse production in right hemisphere stroke survivors with language use impairments. The research characterizes discourse-level language use in right hemisphere stroke (RHD) survivors using RHDBank, an internationally shared multimedia database, and...
- The National Institute on Deafness and Other Communication Disorders awarded The Medical University of South Carolina $420,118 on June 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate transcranial focused ultrasound (TFUS) modulation of olfactory valence in the treatment of parosmia and other qualitative smell disorders. The project targets a therapeutic gap in olfactory dysfunction treatment exposed by the recent pandemic. While...
- The National Institute on Deafness and Other Communication Disorders awarded Purdue University $504,483 on September 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to characterize developmental trajectories that predict persistence or recovery from speech sound disorder in children. The project recruits a large cohort of children with diverse speech abilities at age four and follows them annually through age seven to identify predictive...
- Federal Project Grant Award Summary The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded the University of Missouri System $577,136 on September 15, 2025, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate the role of the cerebellum in predictive motor control for speech production. The three-year project, concluding August 31, 2028, will examine how cerebellar damage contributes to ataxic dysarthria—a speech...
- The National Institute on Deafness and Other Communication Disorders, a component of the National Institutes of Health under the Department of Health and Human Services, awarded $350,000 to The Medical University of South Carolina on July 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate neural plasticity mechanisms in aging adults with hearing loss. The research targets two aspects of brain adaptation to age-related hearing loss:...
- The National Institutes of Health Office of the Director awarded the University of South Carolina $533,224 on March 6, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct longitudinal research on vocal development and social communication outcomes in children with an older sibling diagnosed with autism. The research comprises three aims: contrasting early vocal feature trajectories (including volubility and canonical proportion) in infants at elevated likelihood for...
- The National Institute on Deafness and Other Communication Disorders, part of the Department of Health and Human Services National Institutes of Health, awarded $132,695 to the University of Maryland, College Park on July 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to develop artificial intelligence methods for delivering vocal tract gesture biofeedback in speech sound disorder therapy for children. The work spans two phases through June...
The National Institute on Deafness and Other Communication Disorders, part of the Department of Health and Human Services National Institutes of Health, awarded The Medical University of South Carolina $666,519 on August 15, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to conduct a pragmatic clinical trial evaluating motor speech interventions for hypokinetic dysarthria in individuals with Parkinson's disease across real-world clinical practice settings. Hypokinetic dysarthria, a motor speech disorder affecting approximately 90 percent of individuals with Parkinson's disease, is characterized by reduced speaking volume, imprecise articulation, impaired prosody, and decreased speech intelligibility. While randomized controlled trials have demonstrated the efficacy of motor speech interventions in controlled environments, outcomes and adherence have not been studied in dynamic clinical practice conditions. The trial will examine treatment outcomes and adherence over time for a broad patient population with Parkinson's disease in various practice settings, and will analyze changes in therapy outcomes in the context of patient-, disease-, and healthcare factors to identify determinants of treatment response. The work will also characterize barriers and facilitators to treatment implementation from the perspectives of patients, families, and clinicians. Performance of work takes place in Charleston, South Carolina. The period of performance runs from August 15, 2026, through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $666.5k | 8/17/26 |